Also, previous research has shown that mTOR activities may be higher among patients with breast cancer with earlier (vs. more advanced) stage, lower (vs. higher) grade, smaller (vs. larger) tumors, and ER+ (vs. ER−) tumors (24). This evidence concerns the gene MTOR and breast carcinoma.